H1抗组胺药联合鼻用糖皮质激素治疗过敏性鼻炎的系统评价与Meta分析
该系统评价纳入16项随机对照试验共4026例过敏性鼻炎患者,比较H1抗组胺药联合鼻用糖皮质激素(AH-INCS)与单用鼻用糖皮质激素(INCS)的疗效。结果显示AH-INCS可降低鼻部症状总分(SMD -0.13)和眼部症状总分(SMD -0.12),亚组分析显示鼻用AH-INCS有益而口服AH-INCS无益,疾病特异性生活质量、鼻吸气流量及不良事件无显著差异。结论认为鼻用AH-INCS优于INCS单药,不推荐口服AH-INCS。
要点
- 鼻用抗组胺药联合鼻用糖皮质激素可改善鼻部和眼部症状。
- 口服抗组胺药联合鼻用糖皮质激素未见额外获益,不推荐。
- 联合治疗在生活质量、鼻吸气流量及不良事件方面与单药无显著差异。
核心结论
- 鼻用AH-INCS在改善鼻部和眼部症状方面优于INCS单药治疗过敏性鼻炎。
- 口服AH-INCS不推荐用于过敏性鼻炎的治疗。
研究设计与样本
- 系统评价与Meta分析,检索Medline和Embase数据库。
- 纳入16项随机对照试验,共4026例过敏性鼻炎患者。
- 比较AH-INCS与INCS单药治疗的效果。
主要发现
- AH-INCS较INCS降低鼻部症状总分(SMD -0.13,95%CI -0.19至-0.06,p<0.001;10项试验,3348例)。
- AH-INCS较INCS降低眼部症状总分(SMD -0.12,95%CI -0.20至-0.04,p=0.003;6项试验,2378例)。
- 亚组分析显示鼻用AH-INCS有益(SMD -0.18,95%CI -0.27至-0.09,p<0.001),口服AH-INCS无获益。
- 疾病特异性生活质量无显著差异(SMD -0.07,95%CI -0.16至0.02,p=0.12;6项试验,1981例)。
- 鼻吸气流量无显著差异(MD -0.03 L/min,95%CI -0.57至0.50,p=0.91;1项试验,54例)。
关键数值与推荐
- 鼻部症状总分改善:SMD -0.13(95%CI -0.19至-0.06,p<0.001)。
- 眼部症状总分改善:SMD -0.12(95%CI -0.20至-0.04,p=0.003)。
- 鼻用AH-INCS亚组:SMD -0.18(95%CI -0.27至-0.09,p<0.001)。
临床怎么用
- 对INCS单药反应不佳的过敏性鼻炎患者,可考虑加用鼻用抗组胺药。
- 不推荐口服抗组胺药联合INCS用于改善鼻部和眼部症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A combination of H1 antihistamine (AH) with intranasal corticosteroid (INCS) is commonly prescribed to patients with allergic rhinitis (AR) who have an inadequate response to monotherapy. In this systematic review we aimed to determine the effects of AH combined with INCS (AH-INCS) for treating AR. METHODS: Literature searches were performed using Medline and Embase. Randomized, controlled trials that studied the effects of AH-INCS vs INCS monotherapy for treating patients with AR were included. The primary outcomes were total nasal symptom scores, total ocular symptom scores, and disease-specific quality of life. The secondary outcomes were objective tests for nasal patency and adverse events. RESULTS: Sixteen studies (4026 patients) met the inclusion criteria. Compared with INCS, AH-INCS decreased total nasal symptom scores (standardized mean difference [SMD], -0.13; 95% confidence interval [CI], -0.19 to -0.06; p < 0.001; 10 trials, 3348 patients) and total ocular symptom scores (SMD, -0.12, 95% CI, -0.20 to -0.04; p = 0.003; 6 trials, 2378 patients). Subgroup analysis indicated no benefit with the oral AH-INCS combination but did show benefit with intranasal AH-INCS (SMD, -0.18; 95% CI, -0.27 to -0.09; p < 0.001). There were no significant differences with regard to disease-specific quality of life (SMD, -0.07; 95% CI, -0.16 to 0.02; p = 0.12; 6 trials, 1981 patients), nasal inspiratory flow (MD, -0.03 L/min; 95% CI, -0.57 to 0.50; p = 0.91; 1 trial, 54 patients), or adverse events. CONCLUSION: Intranasal AH-INCS has benefit over INCS on nasal and ocular symptom improvement for treating AR. Oral AH-INCS is not recommended.
引用
- Seresirikachorn K, Chitsuthipakorn W, Kanjanawasee D, et al. Effects of H1 antihistamine addition to intranasal corticosteroid for allergic rhinitis: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2018. PMID: 29917324. doi:10.1002/alr.22166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。